الفهرس 
CD177 expression in peripheral blood neutrophils in health and disease states
List of contentsOnly 14 pages are availabe for public view
 |  | from | 164 |  |  |
| | | from | 164 | | |
Abstract
None of the mutations so far identified in the philadelphia negative chronic myeloproliferative disorders (cMPDs) proved to be specific and therefore cannot be used independently for their molecular classification (renneville et al., 2006; schmitt graeff et al., 2008; mascarenhas et al., 2013; barbui et al., 2016). Similarly, an objective method for evaluating dysplasia is required in myelodysplastic syndromes (MDS) diagnosis and classification (Inaba et al., 2015). The cluster of differentiation 177 (CD177) glycoprotein (gp) is exclusively expressed on human neutrophils. A characteristic feature of CD177 is its unique expression on a neutrophil subpopulation (stroncek et al., 2004; meyerson et al., 2013). CD177 expression appears to be influenced by biologic variables since the percentage and intensity of CD177 are increased in a number of reactive conditions, including sepsis and growth factor therapy. Therefore, it is unclear whether evaluation of CD177 would be informative for detecting myeloid malignancies (meyerson et al., 2013). This work aimed at studying the expression of CD177 on peripheral blood neutrophils, to explore its diagnostic value in health, non clonal and clonal myeloid neoplasms. The CD177 expression was measured by fFlow cytometry (direct technique). Both the MFI and the percentage of positive cells were measured